Patents
Literature
79 results about "Neurotoxicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an adverse effect on the structure or function of the central and/or peripheral nervous system. It occurs when exposure to substance – specifically, a neurotoxin – alters the normal activity of the nervous system in such a way as to cause permanent or reversible damage to nervous tissue. This can eventually disrupt or even kill neurons, which are cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from organ transplants, radiation treatment, certain drug therapies (e.g., substances used in chemotherapy), recreational drug use, and exposure to heavy metals, bites from certain species of venomous snakes, pesticides, certain industrial cleaning solvents, and certain naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness, loss of memory, vision, and/or intellect, uncontrollable obsessive and/or compulsive behaviors, delusions, headache, cognitive and behavioral problems and sexual dysfunction. Note there is strong evidence that chronic mold exposure in homes can lead to neurotoxicity which may not appear for months to years of exposure. All symptoms listed above are consistent with mold mycotoxin accumulation.
Application of compound for inhibiting phosphorylation of ARMC10 in preparation of medicine for antagonizing tin-induced nervous system injury
The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.
Owner:ARMY MEDICAL UNIV
Application of serratia marcescens in preparation of medicine for treating gradual freezing
PendingCN121570501ANervous disorderBacteria material medical ingredientsAmyotrophic lateral sclerosisSerratia species
The invention discloses an application of serratia marcescens in preparation of a medicine for preventing or treating gradual freezing (amyotrophic lateral sclerosis, ALS) or frontotemporal dementia (FTD). Specifically, the serratia marcescens of the present invention can improve the phenotype of an asymptomatic and frontotemporal dementia model S59L by reducing mitochondrial unfolded protein response (UPRmt); meanwhile, expression of excitatory amino acid glutamic acid can be reduced, excitatory neurotoxicity can be relieved, and ALS and FTD phenotypes can be relieved through cooperation of the two.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Toxicity-enhanced neurotoxin recombinant protein and application thereof
ActiveCN120775067BPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsBinding peptideCell membrane
The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.
Owner:NORTHWEST A & F UNIV
Dihydrotriticale flavones, methods for their preparation and uses thereof
The present application relates to the technical field of medicine, and in particular to a dihydrotricin, a preparation method and use thereof, the preparation method comprising the following steps: taking compound A, diisopropylethylamine and bromomethyl methyl ether to prepare compound B; taking compound C, diisopropylethylamine and bromomethyl methyl ether to prepare compound D; taking compound B and compound D, adding sodium hydroxide to prepare compound E; taking compound E, adding hydrochloric acid to prepare dihydrotricin after washing, separation, and concentration. The preparation method realizes efficient and large-scale synthesis of dihydrotricin. It is first confirmed that dihydrotricin can significantly resist A 1‑42 Oligomer-induced neurotoxicity has broad prospects in preventing and treating middle and late AD and delaying the progression of AD.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
ActiveUS12527811B2Polypeptide with localisation/targeting motifOrganic active ingredientsNeurotoxicityImmunotherapy
The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and / or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and / or neurotoxicity.
Owner:RICHARDSON PAUL G
Method for screening key neurotoxic substances in food raw materials and their products by combining caenorhabditis elegans model with metabolomics
This invention discloses a method for screening key neurotoxic substances in food raw materials and their products using a *C. elegans* model combined with metabolomics. Food samples are processed to prepare a stock solution, which is then used to cultivate *C. elegans*. The sample exhibiting the greatest neurotoxicity to the nematodes is identified by analyzing the number of *C. elegans* movements and neuronal fluorescence images. Subsequently, key neurotoxic substances in food are systematically screened using a combination of non-targeted liquid chromatography-tandem mass spectrometry (LC-MS / MS) and a metabolomics platform. This application establishes a novel method for screening neurotoxic substances by combining nematode activity with non-targeted LC-MS / MS determination and a non-targeted metabolic platform, clarifying key neurotoxic substances in food and providing a theoretical basis for food quality control and high-quality development.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY
A photosensitizer targeting beta amyloid and its preparation method and application
The application discloses a photosensitizer targeting beta amyloid, and a preparation method and application thereof. The photosensitizer is a photosensitizer with A-D-A configuration, and a structural formula thereof is shown as formula I. The photosensitizer synthesized in the application has a longer emission wavelength, and after being combined with beta amyloid, the fluorescence signal is obviously enhanced, and can effectively generate singlet oxygen, that is, the photosensitizer can target mark A beta protein, and is used for fluorescence imaging of the A beta protein; and after the photosensitizer synthesized in the application is combined with beta amyloid in the brain of an Alzheimer's disease (AD) model mouse, the cognitive ability of the AD mouse can be effectively improved, A beta-mediated neurotoxicity can be reduced, and clearance of A beta plaques can be promoted, that is, the photosensitizer can be used for early diagnosis and treatment of Alzheimer's disease.
Owner:SOUTH CHINA UNIV OF TECH
Use of fractalkine in the preparation of a medicament for preventing or treating repair of white matter damage
This invention provides the application of fractalkine in the preparation of drugs for the prevention or treatment of white matter injury repair. In animal models of cerebral hemorrhage, it was found that the mass effect of hematoma in the basal ganglia and the neurotoxic products generated by its lysis lead to damage to surrounding white matter fiber bundles. Fractalkine plays an important role in regulating microglial activation after cerebral hemorrhage to promote white matter repair.
Owner:THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
A method and system for assessing car-t treatment-related neurotoxicity based on behavioral characteristics
ActiveCN121003418BDiagnostic signal processingEnsemble learningCross correlation analysisComputational physics
The application discloses a method and system for evaluating CAR-T treatment related neurotoxicity based on behavior characteristics, relates to the technical field of medical behavior analysis, and provides the following scheme, which comprises the following steps: synchronously collecting angular velocity time series data of double upper limbs of a patient and electromyographic signals corresponding to muscle surfaces of the double upper limbs; performing frequency band optimization filtering on the angular velocity time series data of the double upper limbs respectively; generating angular velocity waveforms; taking a wave peak time point of the angular velocity waveform as a reference; extending forward for a preset time length; and calculating an energy integral curve of the electromyographic signals. The angular velocity time series data of the double upper limbs is processed through frequency band optimization to generate angular velocity waveforms, the energy integral curve of the electromyographic signals is extracted forward based on the wave peak time point of the angular velocity, candidate time points are obtained, and local cross-correlation analysis is enabled to locate and intercept points when the wave peak value is lower than a preset threshold, so that the problem of missing weak tremor signals is solved, effective detection and reliable interception of low-amplitude tremors are realized, and weak signal features are avoided from being lost.
Owner:SUN YAT SEN UNIV
Use of gallic acid in the preparation of a medicament for preventing or treating peripheral neuropathy
The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Umami peptide without nervous excitatory toxicity as well as preparation process and application of umami peptide
The invention provides an umami peptide without nervous excitatory toxicity and a preparation process and application thereof, the umami peptide is extracted from broad bean protein, and the amino acid sequence is shown as SEQ ID NO.1 and / or SEQ ID NO.2. Compared with a traditional umami substance-sodium glutamate (monosodium glutamate MSG), the umami peptide has the characteristics of activating umami receptors TAS1R1 / TAS1R3 without acting on sodium glutamate receptors such as NMDA and the like, and has the advantages that the umami peptide can be used for preparing the umami peptide. No NMDA receptor mediated excitatory neurotoxicity exists; meanwhile, the umami peptide can stimulate intestinal endocrine cells (STC-1) to secrete GLP-1.
Owner:ZHEJIANG UNIV
Microorganism-intestine-brain axis-based neurotoxicity antagonist screening and evaluation method
The invention belongs to the field of bioengineering and neurotoxicity prevention and control, and particularly relates to a neurotoxicity antagonist screening and evaluating method based on a microorganism-intestine-brain axis. The screening method of the neurotoxicity antagonist comprises the following steps: establishment of a neurotoxicity animal model, verification of the neurotoxicity model, sequencing of intestinal flora and screening of key flora, coupling analysis of flora-cranial nerve indexes, verification of candidate microorganisms, screening of core bacterial metabolites, verification of the core bacterial metabolites and verification of the core bacterial metabolites. According to the method, through behavior-neurotransmitter-inflammation-gene / mitochondrial function multi-level index linkage, a reproducible recovery index (RI) index is established, and quantitative screening and grading judgment of candidate strains and metabolites of the candidate strains on nerve injury repair are achieved.
Owner:NANJING AGRICULTURAL UNIVERSITY +1
Application of HIF-1alpha inhibitor in preparation of product for inducing transformation of astrocytes from pro-inflammatory type to anti-inflammatory type
The invention belongs to the technical field of biological medicines, and relates to application of an HIF-1alpha inhibitor in preparation of a product for inducing transformation of astrocytes from a pro-inflammatory type to an anti-inflammatory type. The invention reveals that activation of an HIF-1 signal channel is an important mechanism for driving neuroinflammatory response and pro-inflammatory A1 type astrocyte formation, and inhibition of HIF-1 activation can effectively promote generation of neuroprotective A2 type astrocytes. By applying the HIF-1alpha small-molecule inhibitor KC7F2 to astrocytes, HIF-1alpha activation is blocked, and the astrocytes are promoted to be converted from a proinflammatory A1 phenotype to an anti-inflammatory A2 phenotype, so that inflammatory response is inhibited, neurotoxicity is reduced, and a neuron microenvironment is improved. The invention provides a novel intervention strategy based on HIF-1alpha signal regulation and control, and a novel theoretical basis and a novel potential drug treatment scheme are provided for treatment of nervous system injury and related neurodegenerative diseases.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
Caenorhabditis elegans exposure evaluation method based on neural behavior multi-parameter integration
The invention relates to the technical field of biological detection and toxicological evaluation, and discloses a neural behavior multi-parameter integration-based caenorhabditis elegans exposure evaluation method which comprises the following specific steps: S1, synchronous culture of caenorhabditis elegans; s2, pollutant exposure treatment; s3, multi-parameter behavior detection; s4, data standardization processing; and S5, constructing a comprehensive evaluation model, and performing weighted integration on four core parameters including the movement speed, the chemotactic index, the synaptic spot density and the calcium signal amplitude after standardization to construct a neurotoxicity index NTI. According to the method disclosed by the invention, a multi-layer and multi-dimensional neurotoxicity evaluation system is constructed by integrating four types of neurobehavior parameters including motion behaviors, chemotactic reactions, synaptic morphology and neuron calcium signals, and the defect that a traditional single endpoint index cannot comprehensively reflect overall disturbance of a neural regulation network is overcome; by utilizing the high homology of the nervous system of caenorhabditis elegans and the human nerve gene, the clinical correlation and mechanism analysis capability of environmental pollutant neurotoxicity evaluation are remarkably improved.
Owner:SOUTHEAST UNIV
Gel emplastrum for treating oxaliplatin peripheral neurotoxicity and preparation method of gel emplastrum
PendingCN121971569ANervous disorderPharmaceutical non-active ingredientsAngelica Sinensis RootBlood drug concentration
The invention provides a gel emplastrum for treating oxaliplatin peripheral neurotoxicity and a preparation method, and relates to the field of traditional Chinese medicine, the gel emplastrum comprises a backing layer, an emplastrum layer and an anti-sticking layer; the paste layer is a gel layer formed by traditional Chinese medicine extract and a matrix for loading the traditional Chinese medicine extract; the traditional Chinese medicine extract is prepared from a traditional Chinese medicine composition; the traditional Chinese medicine composition comprises astragalus membranaceus, angelica sinensis, vinegar rhizoma sparganii, vinegar curcuma zedoary, cassia twig, achyranthes bidentata and pheretima in a mass ratio of 6: 3: 2: 2: 2: 4: 2. The matrix comprises a framework material, a cross-linking agent, a cross-linking regulator, a thickening agent, a humectant, a complexing agent, pure water, a preservative, a penetration enhancer, a thermal inductance regulator and a high-performance emulsifying thickening agent. The problems that in the prior art, a formula for promoting blood circulation to remove blood stasis is inconvenient to use in a soaking and washing main use mode, the patient compliance is poor, the speed of medicine entering the body of a patient is not easy to control, the blood concentration in the body of the patient is difficult to maintain stably, and the peripheral neurotoxicity treatment progress is difficult to control can be solved.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV
Monoacylglycerol lipase (MAGL) inhibitors for the treatment of pain and related medical disorders
This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.
Owner:YICHANG HUMANWELL PHARMA CO LTD
Application of cGAS-STING pathway inhibitor in relieving AAV-induced neural immune response
The invention relates to the technical field of biological medicine, and particularly discloses application of a cGAS-STING pathway inhibitor in relieving neural immune response induced by AAV, and the technical key points are as follows: it is found that high-dose AAV can activate a cGAS-STING signal pathway in a nervous system, resulting in inflammatory response, glial cell activation, T cell infiltration and neuron damage; the cGAS-STING pathway is inhibited by means of gene knockout (Stin < + / ->), pharmacological inhibition (such as STING inhibitor H-151) or virus-mediated gene knockout (shSTING) and the like, so that the AAV-induced immune response and neurotoxicity can be effectively reduced, and meanwhile, the expression of a transgenic product carried by the AAV vector is improved. The scheme provided by the invention provides a new strategy and means for optimizing the safety-effectiveness balance of AAV gene therapy.
Owner:JINAN UNIVERSITY
High-flux toxicity pre-evaluation substitution method based on acetylcholin esterase target
PendingCN121950997AEnsure comparabilityGuaranteed standardizationHydrolasesMicrobiological testing/measurementEngineeringNerve cells
The invention discloses a high-flux toxicity pre-evaluation substitution method based on an acetylcholin esterase target. By integrating an SH-SY5Y nerve cell endogenous AChE and recombinant exogenous AChE dual detection system and relying on an automatic screening system constructed by integrating core equipment such as an automatic pipetting workstation, a constant-temperature incubator and a multifunctional microplate reader, a high-flux toxicity pre-evaluation substitution method based on an AChE target is successfully established and is used for evaluating the neurotoxicity of a compound, and the method has the advantages of high sensitivity, high sensitivity, high sensitivity and the like. The method solves the limitation that a single screening method in the prior art cannot evaluate factors such as target inhibition, cell permeability and metabolic transformation at the same time, and the method is simple, convenient, rapid, high in accuracy and suitable for large-scale primary screening of the AChE inhibitor and early warning of neurotoxicity risks.
Owner:DALIAN UNIV OF TECH
Anti-epileptic stiff silkworm polypeptide as well as preparation method and application thereof
The invention belongs to the technical field of biological medicines, and provides an anti-epileptic stiff silkworm polypeptide as well as a preparation method and application thereof. The bombyx batryticatus polypeptide is a peptide fragment with an amino acid sequence as shown in SEQ ID No.1, and is RFAFPAWI (PP6). The method comprises the following steps: preparing a peptide extract in stiff silkworm by simulating gastrointestinal digestion, identifying peptide in stiff silkworm polypeptide by using Nano LC-MS / MS, and carrying out difference analysis; differential peptides with potential anti-epileptic activity are obtained through virtual screening, and the anti-epileptic stiff silkworm polypeptide PP6 with potential anti-epileptic activity is synthesized. PP6 has a neuroprotection effect on PC12 cell neurotoxicity damaged by glutamic acid (Glu) by adjusting a GABA signal channel, and has an anti-epileptic effect on an epileptic mouse induced by pentaerythrityl tetrazole (PTZ). Therefore, PP6 may be a new leading peptide compound for developing epileptic drugs, and the anti-epileptic polypeptide can be widely applied to the fields of medicines, foods and the like to achieve the anti-epileptic target.
Owner:SHANXI UNIV OF CHINESE MEDICINE
Metabolite for treating neurological diseases
PCT designated stageWO2026090483A1Organic active ingredientsNervous disorderNeuro-degenerative diseaseNeurotoxicity
The supplementation of an endogenously produced metabolite fructose-2,6-bisphosphate (F2,6BP), or a derivative thereof, was unexpectedly discovered to have a profound effect on neurological disorders associated with double strand break, including but not limited to neurodegenerative diseases such as polyglutamine diseases. F2,6BP metabolite compositions and methods of use surprisingly restored polynucleotide kinase 3'-phosphatase (PNKP) activity to provide enhanced genome integrity, reduction of pathological aggregate species, reduction of neurotoxicity, and rescue of complex physiological behavior.
Owner:RGT UNIV OF CALIFORNIA
Chimeric antigen receptor targeting MUC16 and application thereof in tumor treatment
PendingCN122060078AVirusesAntibody mimetics/scaffoldsSingle-Chain AntibodiesNatural Killer Cell Inhibitory Receptors
The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a chimeric antigen receptor targeting MUC16 and application of the chimeric antigen receptor in tumor treatment. Specifically, aiming at MUC16 molecules, a single-chain antibody with high affinity is successfully prepared, on the basis of high-affinity scFv, a CAR carrier and CAR-NK cells for recognizing MUC16 are constructed, PD1 of the CAR-NK cells is further knocked out through a CRISPR / Cas9 system, immune cell depletion is reduced, and then the purpose of synergistically and effectively treating tumors is achieved. According to the invention, severe cytokine storm, neurotoxicity or graft versus host disease can be avoided, the side effect is small, and immune escape can be prevented. Moreover, the NK92 cell line can be amplified and passaged infinitely, and the cost is lower, so that the NK92 cell line is more suitable for treating solid tumors, and has a good practical application value.
Owner:SHANDONG UNIV SHENZHEN RES INST +2
Application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease
ActiveCN119236096BNervous disorderPharmaceutical non-active ingredientsAntiparkinson medicationCell membrane
This invention discloses the application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease. GRP94 is highly upregulated on the cell membranes of dopaminergic neurons in the substantia nigra of Parkinson's disease cells, while its expression is extremely low on the surface of normal brain cells. The invention also discloses the application of GRP94 as a target in a targeted delivery system for anti-Parkinson's disease drugs. By targeting GRP94, the delivered anti-Parkinson's drug can efficiently penetrate the blood-brain barrier to reach the brain parenchyma, avoiding normal brain cells and specifically targeting dopaminergic neurons in the substantia nigra of Parkinson's disease cells, thus achieving targeted drug delivery for Parkinson's disease. This invention applies GRP94 as a target in the construction of drug carriers for Parkinson's disease and in the preparation of targeted delivery systems for anti-Parkinson's disease drugs. Compared to other target receptors that cross the blood-brain barrier for targeted brain delivery, targeting GRP94 more specifically targets dopaminergic neurons in the substantia nigra, avoiding drug accumulation and neurotoxicity in normal intracranial regions.
Owner:SUZHOU UNIV
Aryl alkyl azole derivative as well as preparation method and application thereof
The invention belongs to the technical field of medicines, and particularly relates to an aryl alkyl azole derivative as well as a preparation method and application thereof. Benzo [d] [1, 3] thiazine is used as aryl and is directly connected with 4H-1, 2, 4-triazole-4-yl through a chemical bond, and alkoxy is introduced to the C6 position of the aryl, so that the aryl alkyl azole derivative is obtained. The compound disclosed by the invention is novel in structure, shows excellent anti-convulsion activity in two epilepsy models of maximum electroshock and subcutaneous pentyltetrazole as a GABAA receptor agonist, and particularly shows an extremely high protection index, PIgt, in the subcutaneous pentyltetrazole model; and 10, the compound has the remarkable advantages of various action mechanisms, wide therapeutic window and low neurotoxicity, can be used for preparing the anti-epilepsy medicine, and is particularly suitable for treating intractable epilepsy.
Owner:BENGBU MEDICAL COLLEGE
Nanogold loaded ns9283 targeted long-acting analgesic drug and preparation method thereof
The present application relates to nano gold loaded NS9283 targeted long-acting analgesic drug and preparation method. NS9283 is loaded on the surface of sodium citrate coated gold nanoparticles by ligand exchange method, and then Pickering emulsion method is used to construct amphiphilic Janus AuNPs self-assembly microcapsules. The drug has the following advantages: stability is improved, long-term activity is maintained at room temperature; targeted controlled release, in vivo fluorescence imaging shows that the drug is continuously enriched at the nerve injury site for more than 7 days; long-acting analgesia: analgesic effect lasts for 28 days after local administration, which is at least 4 times higher than that of free NS9283; safety guarantee: no neurotoxicity is caused after continuous administration for 14 days, and there is no significant difference in mouse weight, motor coordination and main organ function compared with the control group. The drug provides a safe and efficient treatment scheme for chronic pain.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
Application of glutamine in prevention and / or treatment of lead poisoning
The invention relates to an application of glutamine in prevention or treatment of lead neurotoxicity. Researches show that glutamine has an obvious improvement effect on neurological behavior damage and neuroinflammatory response caused by lead poisoning. The novel application of glutamine provides a novel drug choice for the treatment of lead poisoning, especially the treatment of lead neurotoxicity, and has great application potential and value.
Owner:SOUTHERN MEDICAL UNIVERSITY
AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-beta OLIGOMERS AND DIAGNOSTIC METHODS
Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high M binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds can also label the Aβ species in the brain sections of transgenic AD mice, as shown by immunostaining with an Aβ antibody. Certain amphiphilic compounds were found to alleviate the Cu2+-Aβ induced toxicity in cell viability assays. Additionally, two compounds, ZY-15-MT and ZY-15-OMe, were found to disrupt the interactions between Aβ oligomers and human neuroblastoma SH-SY5Y cell membranes. These studies show compounds with amphiphilic properties that target Aβ oligomers and modulate the Aβ oligomer-cell membrane interactions can be effective as small molecule AD therapeutics. Also, the disclosed amphiphilic dicyanomethylene compounds that can emit in the near-infrared region and chelate copper can be used as early diagnostic agents for AD.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
An antibacterial composition and its application
This invention belongs to the field of medical and pharmaceutical technology, and specifically relates to an antibacterial composition and its application. It comprises osimertinib mesylate and polymyxin. This invention is the first to demonstrate the novel pharmaceutical use of osimertinib mesylate as a synergistic antibacterial adjuvant for polymyxin. Experimental results show that osimertinib mesylate can significantly enhance the antibacterial activity of polymyxin against multidrug-resistant Gram-negative bacteria, effectively reduce the minimum inhibitory concentration of polymyxin, thereby reducing the clinical dosage of polymyxin and lowering the risk of its inherent nephrotoxicity and neurotoxicity. Furthermore, this invention reveals that the combined use of osimertinib mesylate and polymyxin can delay or reverse bacterial resistance to polymyxin, improve the survival rate of infected animal models, and broaden the antibacterial spectrum.
Owner:JILIN UNIVERSITY
Application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine
The invention relates to application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine. Rat and SH-SY5Y cell experiments are carried out, and the rat experiments prove that after intervention of different doses of GSPE, the SOD activity and the GSH content are improved, the MDA level is reduced, the antioxidant capacity of rats is recovered, autophagy is promoted, the filial generation learning and memory retention capacity is remarkably recovered, the autonomous activity capacity is recovered, anxiety behaviors are reduced, the occurrence and development processes of dental fluorosis are slowed down, and the occurrence and development of dental fluorosis are promoted. The change trends of different doses of GSPE present dose dependence, and the protection effect of a high-dose combined intervention group is most significant; in an SH-SY5Y cell experiment, the activity of the cells is improved through GSPE pretreatment, the expression quantity of cleave-caspase3 and cleaved-PARP is remarkably reduced, the autophagy process of the SH-SY5Y cells is promoted, and then the neurotoxicity caused by NaF is relieved. NaF is used as a representative, the prevention and treatment effects of GSPE on the fluorine-induced neurotoxicity are researched, and it is proved that GSPE can inhibit the NaF-induced neurotoxicity, so that the application of autophagy in preparation of drugs or health food for improving the fluorine-induced neurotoxicity from grape seed procyanidine is provided.
Owner:SHIHEZI UNIVERSITY
Grin2b stably transfected cell strain, construction method and application thereof, and method for screening pollutant high-throughput neurotoxicity or learning and memory disorders
The invention discloses a Grin2b stably transfected cell strain, a construction method and application thereof and a method for screening pollutant high-throughput neurotoxicity or learning and memory disorders, and belongs to the technical field of biologication.The construction method comprises the following steps that 1, cells are cultured; (2) constructing a plasmid vector, wherein the plasmid vector comprises a Grin2b coding sequence; (3) virus coating and virus collection; (4) testing the titer of the lentivirus; (5) stable plant screening; and (6) carrying out stable plant transformation function verification. The Grin2b stably transfected cell strain based on the Grin2b related ion channel constructed by the invention provides a brand new technical platform for high-throughput neurotoxicity recognition, learning memory screening and mechanism research of organic pollutants and degradation products thereof.
Owner:SHANGHAI HUADAI BIOTECHNOLOGY CO LTD +1
A non-neurotoxic vsv vector recombinant oncolytic virus carrying sindbis virus g protein
The application discloses a non-neurotoxic VSV vector recombinant oncolytic virus carrying a Sindbis virus G protein, and is a self-replicating recombinant oncolytic virus VSV-SING which is obtained by replacing the G protein coding gene of a wild type VSV with the G protein coding gene of a Sindbis virus through reverse genetic manipulation technology, and has non-neurotoxicity and high oncolytic activity.
Owner:ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD